Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Other Non-Current Liabilities (2016 - 2025)

Collegium Pharmaceutical has reported Other Non-Current Liabilities over the past 5 years, most recently at $19000.0 for Q3 2025.

  • Quarterly results put Other Non-Current Liabilities at $19000.0 for Q3 2025, down 99.54% from a year ago — trailing twelve months through Sep 2025 was $19000.0 (down 99.54% YoY), and the annual figure for FY2024 was $1.2 million, changed.
  • Other Non-Current Liabilities for Q3 2025 was $19000.0 at Collegium Pharmaceutical, down from $38000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for COLL hit a ceiling of $4.1 million in Q3 2024 and a floor of $19000.0 in Q3 2025.